UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean.

Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment.

For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed.

The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction.

The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Per Protocol Population:

All randomized participants who received any study drug and did not violate any relevant important protocol deviations affecting the primary efficacy endpoint.

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean.

Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment.

For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed.

The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction.

The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Per Protocol Population:

All randomized participants who received any study drug and did not violate any relevant important protocol deviations affecting the primary efficacy endpoint.

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean.

Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment.

For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed.

The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction.

The MMRM includes UACR values at protocol specified visits from Day 85 up to Day 169.

Per Protocol Population:

All randomized participants who received any study drug and did not violate any relevant important protocol deviations affecting the primary efficacy endpoint.

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean.

Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment.

Only participants with values at Baseline and Day 169 are included.

Per Protocol Population:

All randomized participants who received any study drug and did not violate any relevant important protocol deviations affecting the primary efficacy endpoint.

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean.

Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment.

For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed.

The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction.

The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Full Analysis Population:

All randomized participants who received any study drug.

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean.

Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment.

For the intercurrent events, if a subject is lost to follow-up (EOT), discontinues treatment due to AE, or uses prohibited medication, the UACR data are treated as missing on or after the event and no imputation is performed.

The LS means of percent change and difference in percent change, corresponding 90% confidence intervals are calculated based on a mixed model with repeated measures (MMRM) of log (UACR post-baseline/UACR baseline) as the response, adjusting for fixed effects of treatment, visit, and treatment-by-visit interaction, SGLT2i, region (Japan or ROW), baseline log UACR, and baseline log UACR-by-visit interaction.

The MMRM includes UACR values at protocol specified visits from baseline up to Day 169.

Full Analysis Population:

All randomized participants who received any study drug.

UACR values are collected as triplicates at baseline and at each CSP planned visit. For each triplicate, the UACR are averaged with geometric mean.

Baseline is defined as the geometric mean of UACR measurements prior to first dose of study treatment.

Only participants with values at Baseline and Day 169 are included.

Full Analysis Population:

All randomized participants who received any study drug.

ADA prevalence: number of participants ADA positive (ADA+) at baseline and/or post-baseline.

Treatment-induced ADA+: ADA not detected or missing at baseline and at least one post-baseline ADA+.

Treatment-boosted ADA+: ADA+ at baseline and baseline titre is boosted by ≥ 4-fold increase at ≥ 1 post-baseline time point.

Treatment-emergent ADA+ (TE-ADA + or ADA incidence): Treatment-induced ADA+ OR and Treatment-boosted ADA+.

PK Analysis Population:

All subjects who are randomized and receive any study drug who have at least one detectable MEDI3506 serum concentration measurement post-treatment.

MEDI3506/Tozorakimab serum concentrations were measured using a validated assay method.

PK Analysis Population:

All subjects who are randomized and receive any study drug who have at least one detectable MEDI3506 serum concentration measurement post-treatment.

Participants were tested for COVID-19 during the course of the study. Descriptive analysis of asymptomatic participants tested positive for COVID-19 during the study.

Safety Analysis Population:

All randomized participants who received any study drug.

Subset of participants tested positive for COVID-19 during the study.

For participants tested positive for COVID-19 during the intervention and follow-up periods, this analysis provides:

• the number and proportion of subjects with any treatment-emergent adverse event
• the number and proportion of subjects with any treatment-emergent serious adverse event